NCT03692325View on ClinicalTrials.gov

Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia

PHASE2CompletedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

December 5, 2018

Primary Completion Date

September 1, 2022

Study Completion Date

August 30, 2024

Conditions

Leukoplakia, Oral

Interventions

DRUG

Nivolumab

Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03692325 - Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia | Biotech Hunter | Biotech Hunter